0001477932-26-002218
SEC filingBioNexus reported FY2025 revenue of $7.4M with a net loss of -$3.0M, as operational challenges at the Chemrex subsidiary offset gross margin improvements. Liquidity remains dependent on working capital management and the successful remediation of internal control deficiencies.
BioNexus Gene Lab Corp. generated revenue of $7.4 million for fiscal year 2025, resulting in gross profit of $1.1 million and a gross margin of 14.6%. The gross margin percentage for the Chemrex segment improved compared to the prior year, primarily attributable to a different product mix in sales. This improvement in margin structure provides a degree of financial resilience, even as the broader revenue base faced pressure. The company's ability to maintain positive gross profitability demonstrates that core operations remain viable despite volume headwinds.
The company reported an operating loss of -$3.0 million, representing an operating margin of -39.9%. This loss was driven by revenue declines that outpaced reductions in operating expenses. The net loss of -$3.0 million reflects the challenges of maintaining profitability amid operational disruptions. Management's principal areas of focus during fiscal year 2025 included liquidity management, remediation of internal control and governance issues identified at Chemrex, support for ongoing subsidiary operations, and the evaluation of strategic opportunities in diagnostics-related businesses.
A significant development for investors is the disclosure of material weaknesses in internal control over financial reporting, specifically located at the Chemrex subsidiary. The Audit Committee investigation revealed transactions executed without proper Board approval, including unauthorized remuneration increases and a cancelled property sale. Management has initiated a remediation plan involving revised delegation of authority policies and strengthened oversight. This governance gap directly connects to the operational issues, as the change of management cited for the revenue decline occurred within this context of control breakdown, creating a dual risk profile of both operational underperformance and compliance failures.
MRNA Scientific's broader expansion would depend on a range of factors, including available capital, commercial demand, operating capacity, regulatory considerations, and strategic partnerships. As commercialization efforts build and research activities expand, operating expenses and capital requirements are expected to increase significantly. The company continues to receive a significant portion of its revenues from genomic screening products, making adoption rates of these products critical to future performance.